📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-21 08:52
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
41 announcements match the current filters (relevance ≥ 5).
Glenmark launches Calcium Gluconate Injection in US targeting $69.9M market
Glenmark Pharmaceuticals Inc., USA has launched Calcium Gluconate Injection USP in 1,000 mg/10 mL, 5,000 mg/50 mL Single-Dose Vials, and 10,000 mg/100 mL Pharmacy Bulk Packages. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi USA's reference listed drug (NDA 208418). According to IQVIA sales data for the 12-month period ending June 2026, the US market size for this product was approximately $69.9 million. This launch expands Glenmark's institutional injectables and hospital offerings in the US market.
Confidence: HIGH
What changedGlenmark launched generic Calcium Gluconate Injection USP in three strengths/vial formats in the US market.
Why it mattersStrengthens Glenmark's US hospital injectables footprint, providing incremental revenue flow against generic price erosion.
US Market Size (12M to June 2026): $69.9 millionMarket size vs TTM revenue (Rs 17,737 Cr): ~3.3%Available Presentations: 3 formats
📅 Short termCommercial rollout begins immediately; incremental sales will gradually contribute to North American formulation revenue over the next few quarters.
📈 Long termAligns with Glenmark's strategy to build a differentiated and resilient institutional injectables portfolio in the US market.
⚠ Risk flags
- Generic competition and price erosion in the US market
- Market share capture rate vs established competitors
Key Highlights
Commercial launch of Calcium Gluconate Injection USP across three vial configurations in the US
Targeted US addressable market size of approximately $69.9 million for the 12-month period ending June 2026
Therapeutically equivalent to reference listed drug of Fresenius Kabi USA, LLC (NDA 208418)
👀 What to Watch
Monitor market share ramp-up and pricing trends in Glenmark's US injectables segment during upcoming quarterly financial reports.
Glenmark receives US FDA approval for generic Flonase Nasal Spray ($295.2M market)
Glenmark Pharmaceuticals has secured US FDA approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. The approved product is bioequivalent and therapeutically equivalent to Haleon's Flonase Nasal Spray. According to IQVIA data for the 12 months ending June 2026, the relevant US market achieved annual sales of approximately $295.2 million. The product will be commercialized and distributed across the US through Glenmark Pharmaceuticals Inc., USA.
Confidence: HIGH
What changedGlenmark gained final regulatory clearance from the US FDA to market generic Fluticasone Propionate Nasal Spray in the United States.
Why it mattersStrengthens Glenmark's respiratory formulation portfolio in the key US market, targeting an addressable market pool of $295.2 million.
US Market Size (Flonase): $295.2 millionDosage Strength: 0.05 mg (50 mcg)/sprayMarket Period Reference: 12-month period ending June 2026
📅 Short termPositive sentiment driver for the US business segment following the approval.
📈 Long termSupports Glenmark's strategy to revive and expand its US generics and respiratory franchise with higher-barrier formulation products.
⚠ Risk flags
- Pricing erosion and market share competition from other generic competitors in the US respiratory segment
- Product approval limited strictly to indications listed on Glenmark's approved label
Key Highlights
US FDA approval received for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray
Therapeutic generic equivalent to reference listed drug Flonase (Haleon US Holdings LLC)
Targeted US market size is approximately $295.2 million for the 12 months ended June 2026
Commercial distribution to be handled directly by Glenmark Pharmaceuticals Inc., USA
👀 What to Watch
Track the commercial rollout timeline in the US market and look for revenue contribution from this launch in upcoming quarterly results.
$15.28 Million Settlement with Humana Inc. in US Antitrust Litigation
Glenmark Pharmaceuticals' US subsidiary has entered into a settlement agreement with Humana Inc. for $15.28 million (approx. ₹127 Cr) to resolve antitrust litigation. The settlement addresses allegations of price-fixing and anti-competitive conduct involving generic drugs, which Glenmark continues to deny. The payment will be made in two installments and has already been fully provided for in the company's financial statements. This settlement is part of a larger consolidated legal matter involving over 35 complaints and 46 state attorneys general.
Confidence: HIGH
What changedGlenmark has reached a definitive settlement with one major plaintiff (Humana Inc.) in its long-running US antitrust litigation, moving from active dispute to a scheduled payout.
Why it mattersWhile the settlement amount is relatively small (~0.75% of TTM Revenue), it represents progress in clearing a significant legal overhang that has persisted since 2016.
Settlement Amount: $15.28 millionSettlement vs TTM Revenue: ~0.75%Settlement vs TTM PAT: ~9.3%Total Complaints since 2016: 35+State Attorneys General involved: 46
📅 Short termThe news is likely to be viewed neutrally by the market as the financial impact was already provisioned and the settlement amount is manageable.
📈 Long termResolving these legacy antitrust issues is crucial for Glenmark to reduce legal contingencies and focus on its 'Glenmark 3.0' strategy and innovation pipeline.
⚠ Risk flags
- Ongoing litigation with 46 state attorneys general
- Potential for further settlements with other direct and indirect purchaser classes
Key Highlights
Settlement amount of $15.28 million ($15,285,369) including interest to be paid in two installments
Resolves 3 specific complaints filed by Humana Inc. within a larger consolidated litigation framework
Glenmark USA has been named in more than 35 similar complaints since 2016 regarding generic drug pricing
Full settlement amount has already been provided for in the company's financials, resulting in no fresh P&L impact
Litigation involves 46 state attorneys general and various classes of purchasers
👀 What to Watch
Investors should monitor the progress of the remaining 32+ antitrust complaints and the status of the litigation involving the 46 state attorneys general to gauge total potential liability.
23.1% Revenue Growth: Glenmark Reports Q1 FY27 PAT of ₹482.8 Cr with Strong Global Momentum
Glenmark Pharmaceuticals reported a robust start to FY27 with consolidated revenue rising 23.1% YoY to ₹4,018.5 Cr. EBITDA grew 38.6% to ₹804.8 Cr, achieving a 20.03% margin, driven by double-digit growth across all key geographies. North America revenue surged 41.1% (19.8% excluding one-time licensing income), while the India business grew 15.5%, continuing to outperform the Indian Pharmaceutical Market (IPM). Profit After Tax (PAT) stood at ₹482.8 Cr, a significant recovery from the low base of ₹4.7 Cr in the previous year's corresponding quarter.
Confidence: HIGH
What changedGlenmark has transitioned from a period of volatility to broad-based growth across India, US, Europe, and Emerging Markets, supported by a stronger balance sheet following the Glenmark Life Sciences stake sale.
Why it mattersThe results validate the 'Glenmark 3.0' strategy of focusing on branded and specialty products (like Ryaltris and Winlevi) to drive higher margins and reduce reliance on commoditized generics.
Q1 FY27 Revenue: ₹4,018.5 CrQ1 FY27 PAT: ₹482.8 CrEBITDA Margin: 20.03%India Market Share: 2.37%Q1 Revenue vs TTM Revenue: 23.66%
📅 Short termThe stock is likely to react positively to the strong margin expansion and double-digit growth across all segments, especially the recovery in the US and India markets.
📈 Long termStructural focus on innovation-led platforms and specialty respiratory/dermatology products provides a path toward the company's 25% EBITDA margin target.
⚠ Risk flags
- Dependence on deferred out-licensing income for North America growth spike
- Regulatory risks associated with US FDA inspections of manufacturing facilities
Key Highlights
Consolidated revenue reached ₹4,018.5 Cr, representing approximately 23.6% of the TTM revenue.
North America revenue grew 41.1% YoY to ₹1,097.4 Cr, aided by deferred out-licensing income for ISB 2001.
India formulation business grew 15.5% YoY to ₹1,432.1 Cr, outpacing the IPM growth of 12.2%.
EBITDA margin improved to 20.03% from 17.78% in the year-ago period.
Consumer Care business (GCC) recorded 28% YoY growth, with the flagship Candid brand growing over 30%.
👀 What to Watch
Investors should monitor the sustainability of North American margins excluding one-time licensing gains and track the clinical progress of the innovation pipeline, specifically ISB 880 and ISB 830 which are entering Phase 2 trials.
Glenmark Q1 PAT Surges to ₹482.8 Cr; Dividend Record Date Set for Aug 31, 2026
Glenmark Pharmaceuticals reported a strong turnaround in Q1 FY27, with consolidated net profit reaching ₹482.83 Cr, a significant jump from ₹46.97 Cr in the same quarter last year. Consolidated revenue from operations grew 23.1% YoY to ₹4,018.48 Cr. The company has fixed August 31, 2026, as the record date for dividend entitlement for the financial year ended March 31, 2026. Additionally, the board approved amendments to key corporate policies and reconstituted the Risk Management Committee.
Confidence: HIGH
What changedGlenmark has transitioned from a low-profit base in the previous year to robust profitability in Q1 FY27, while also formalizing the timeline for its annual dividend distribution.
Why it mattersThe sharp recovery in profitability and 23% revenue growth indicates improved operational efficiency and successful execution of its branded-led portfolio strategy, which targets higher pricing power.
Q1 FY27 Consolidated Revenue: ₹4,018.48 CrQ1 FY27 Consolidated PAT: ₹482.83 CrRevenue vs TTM Revenue: ~23.6%YoY PAT Growth: 927.9%Dividend Record Date: August 31, 2026
📅 Short termThe stock is likely to react positively in the short term due to the significant earnings beat and the confirmation of the dividend record date.
📈 Long termThe long-term outlook depends on the company's ability to maintain 25% EBITDA margins and successfully launch new products in the US and European markets under its innovation strategy.
⚠ Risk flags
- US market regulatory risks
- Generic pricing pressure
- Distributor inventory uncertainty
Key Highlights
Consolidated Revenue from operations increased 23.1% YoY to ₹4,018.48 Cr from ₹3,264.44 Cr.
Consolidated Net Profit surged to ₹482.83 Cr compared to ₹46.97 Cr in Q1 FY26.
Basic Earnings Per Share (EPS) for the quarter improved to ₹17.11 from ₹1.66 YoY.
Record date for dividend entitlement is fixed as August 31, 2026, with the AGM scheduled for September 11, 2026.
Standalone revenue for the quarter stood at ₹2,434.99 Cr with a PAT of ₹735.64 Cr.
👀 What to Watch
Investors should monitor the sustainability of these improved margins and the execution of the 'Glenmark 3.0' strategy, particularly the innovation-led growth and debt reduction targets.
₹4,018 Cr Revenue: Glenmark Reports 23% YoY Growth and 60% QoQ PAT Surge in Q1 FY27
Glenmark Pharmaceuticals reported a strong start to FY27 with consolidated revenue of ₹4,018.48 cr, representing a 23.1% YoY growth compared to ₹3,264.44 cr. Net profit (PAT) for the quarter reached ₹482.83 cr, a significant jump from ₹46.97 cr in the same period last year and a 60.2% sequential increase from Q4 FY26. The company also announced August 31, 2026, as the record date for the FY26 dividend. Finance costs showed a slight reduction to ₹53.99 cr from ₹58.23 cr YoY, reflecting improved balance sheet management.
Confidence: HIGH
What changedGlenmark has reported its Q1 FY27 financial results, showing a sharp recovery in profitability and steady top-line growth compared to the previous year.
Why it mattersThe significant jump in PAT and sequential revenue growth indicates that the company's shift toward branded products and operational efficiencies is beginning to reflect in the bottom line, supporting its 25% EBITDA margin target.
Consolidated Revenue (Q1 FY27): ₹4,018.48 crConsolidated PAT (Q1 FY27): ₹482.83 crYoY Revenue Growth: 23.1%QoQ PAT Growth: 60.2%Q1 Revenue vs TTM Revenue: 23.6%
📅 Short termThe stock is likely to react positively to the strong earnings beat, especially the substantial YoY growth in net profit and sequential improvement.
📈 Long termIf the company maintains this growth trajectory and continues reducing finance costs, it validates the structural turnaround following the Glenmark Life Sciences stake sale and the AbbVie deal.
⚠ Risk flags
- Generic pricing pressure in the US market
- Regulatory compliance risks across global manufacturing sites
- Inventory management volatility as seen in previous quarters
Key Highlights
Consolidated revenue from operations increased 23.1% YoY to ₹4,018.48 cr
Consolidated PAT surged to ₹482.83 cr from ₹46.97 cr in Q1 FY26
Basic EPS for the quarter improved to ₹17.11 compared to ₹1.66 in the year-ago period
Finance costs decreased to ₹53.99 cr from ₹58.23 cr YoY
Record date for FY26 dividend entitlement set for August 31, 2026
👀 What to Watch
Investors should monitor the sustainability of these improved margins and the execution of the 'Glenmark 3.0' strategy, specifically the impact of new product launches in the US and Europe.
$1.6 Billion Market Opportunity: Glenmark Launches Sugammadex Injection in the USA
Glenmark Pharmaceuticals Inc., USA has launched Sugammadex Injection, a generic version of Merck's BRIDION®, in the US market. The product targets an addressable market valued at approximately $1.6 billion (Rs 13,280 Cr) based on IQVIA sales data for the 12 months ending May 2026. This 'Day 1' launch is a strategic move to strengthen Glenmark's injectable portfolio in the US hospital and institutional segment. Given Glenmark's TTM revenue of Rs 16,983 Cr, this launch addresses a market equivalent to nearly 78% of the company's current annual turnover.
Confidence: HIGH
What changedGlenmark has successfully launched a generic version of a high-value injectable drug in the US market immediately upon patent/exclusivity availability.
Why it mattersThe US market is a key focus for Glenmark's revival strategy; entering a $1.6 billion market segment helps offset generic price erosion in other parts of the portfolio and supports the target of 25% EBITDA margins.
Addressable US Market Size: $1.6 billionMarket Size vs TTM Revenue: ~78%TTM Revenue: Rs 16,983 CrProduct Strengths: 200 mg/2 mL and 500 mg/5 mL
📅 Short termThe 'Day 1' launch is likely to be viewed positively by the market as it demonstrates operational agility and provides immediate revenue potential.
📈 Long termThis launch is part of the 'Glenmark 3.0' strategy to build a branded-led and innovative portfolio, reducing reliance on commoditized generics.
⚠ Risk flags
- Generic price erosion
- Competition from other generic manufacturers
- Regulatory compliance at manufacturing facilities
Key Highlights
Targeting a US market with annual sales of approximately $1.6 billion as of May 2026
Launched two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials
Achieved a 'Day 1' launch, indicating high execution discipline and regulatory preparedness
Product is bioequivalent and therapeutically equivalent to the reference drug BRIDION®
Strengthens presence in the high-margin hospital and institutional segment in North America
👀 What to Watch
Monitor US revenue growth and market share capture for Sugammadex over the next 2-3 quarters to see if it meaningfully contributes to the company's 15% growth target.
U.S. FDA Approves RYALTRIS® Expansion for Children Aged 6 to <12 Years
Glenmark has received U.S. FDA approval to expand the use of its flagship respiratory product, RYALTRIS® Nasal Spray, to children aged 6 to less than 12 years. This expansion targets a significant demographic, as approximately 25% of U.S. children in this age group were diagnosed with seasonal allergies in 2024. The approval is particularly timely as Glenmark transitioned to direct commercialization of RYALTRIS® in the U.S. on April 1, 2026, allowing the company to capture higher margins from this branded specialty product. This move aligns with the company's strategy to reach 25% EBITDA margins by shifting from commoditized generics to branded innovation.
Confidence: HIGH
What changedThe U.S. FDA has expanded the approved age range for RYALTRIS® from 12+ years to include children as young as 6 years old.
Why it mattersThis significantly increases the addressable market for Glenmark's key innovative brand in the U.S. and supports the transition to a higher-margin, branded-led business model (Glenmark 3.0).
Target Age Group Expansion: 6 to <12 yearsGlobal Market Presence: 56 countriesPhase 3 Study Size: 446 childrenDirect Commercialization Date: April 1, 2026TTM Revenue: Rs 16,983 Cr
📅 Short termThe approval provides a positive regulatory catalyst and strengthens the company's competitive position in the U.S. respiratory market for the upcoming allergy seasons.
📈 Long termThis is a structural step in Glenmark's evolution toward an innovation-led specialty pharma company, reducing its dependence on the volatile U.S. generic pricing environment.
⚠ Risk flags
- Execution risk in direct U.S. commercialization
- Potential side effects monitoring (epistaxis, somnolence) as per FDA label
Key Highlights
U.S. FDA approval expanded to include pediatric patients aged 6 to less than 12 years for Seasonal Allergic Rhinitis.
Approval supported by a Phase 3 study involving 446 children aged 6 to 11 years.
RYALTRIS® is now approved in 56 countries globally, with 11 new market launches in FY26.
Glenmark assumed direct commercialization and distribution in the U.S. effective April 1, 2026.
U.S. CDC data indicates 25% of children aged 6-11 had diagnosed seasonal allergies in 2024.
👀 What to Watch
Investors should monitor the U.S. revenue growth in upcoming quarterly results to gauge the impact of direct commercialization and this label expansion. The key metric to watch is the improvement in EBITDA margins toward the company's 25% target as the product mix shifts toward branded specialty assets.
Glenmark launches Olanzapine Injection in US, targeting $25.4 million market
Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection (10 mg/vial), a generic version of Zyprexa®. The addressable market for this product in the US is approximately $25.4 million (approx. ₹212 crore) as of May 2026. This launch is part of Glenmark's strategic shift toward a robust injectables portfolio and strengthening its institutional channel presence. While the individual product market is small relative to Glenmark's ₹16,983 crore TTM revenue, it supports the company's goal of improving margins through complex generics.
Confidence: HIGH
What changedGlenmark has added a new injectable product to its US portfolio, moving beyond commoditized oral solids.
Why it mattersInjectables typically have higher entry barriers and better pricing stability than standard generics, supporting Glenmark's '3.0 strategy' for margin expansion.
Annual Market Size (IQVIA): $25.4 millionMarket Size vs TTM Revenue: ~1.25%Dosage Strength: 10 mg/vialTTM Revenue: ₹16,983 Cr
📅 Short termThe launch provides a minor positive sentiment boost as it demonstrates execution of the US product pipeline.
📈 Long termContributes to the structural shift toward complex generics and injectables, which is critical for long-term margin sustainability in the US market.
⚠ Risk flags
- Generic price erosion
- Competition from other generic manufacturers
Key Highlights
Launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the US market.
Addressable market size of approximately $25.4 million for the 12-month period ending May 2026.
Product is bioequivalent and therapeutically equivalent to the reference drug Zyprexa® by Cheplapharm.
Strategic focus on expanding the injectables portfolio to meet institutional channel needs.
👀 What to Watch
Watch for the cumulative impact of new US injectable launches on the company's North American revenue and its progress toward the 25% EBITDA margin target.
Glenmark Advances Phase 3 Clinical Trial for Trastuzumab rezetecan in Ovarian Cancer
Glenmark Specialty S.A. has initiated patient enrollment in India for a Phase 3 clinical trial of Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody-drug conjugate (ADC). This trial targets platinum-resistant ovarian cancer, a high-unmet-need area where India has a significant disease burden. The drug is licensed from Hengrui Pharma, which has already secured Breakthrough Therapy Designations for 9 indications in China. This advancement supports Glenmark's 'Glenmark 3.0' strategy of building a branded, innovation-led oncology pipeline to drive its 15% annual growth target.
Confidence: HIGH
What changedGlenmark has progressed from licensing the ADC asset to active Phase 3 clinical trial execution in India, marking a concrete step toward commercialization in its licensed territories.
Why it mattersADCs represent a high-growth segment in oncology; successful development would validate Glenmark's R&D strategy and support its target of 25% EBITDA margins by shifting toward branded, innovative products.
TTM Revenue: ₹ 16,983 CrBreakthrough Therapy Designations (China): 9Annual Capex Plan: ₹ 700-800 CrGlobal Ovarian Cancer Rank: 8th most common
📅 Short termPositive sentiment is expected as the company demonstrates progress in its innovative pipeline, though no immediate revenue impact will occur until clinical trials conclude and approvals are granted.
📈 Long termStructurally significant as it builds Glenmark's oncology presence; however, the exclusion of major markets like the US and Europe from the licensing deal limits the total addressable market for this specific asset.
⚠ Risk flags
- Clinical trial failure risk
- Regulatory approval delays in Australia/South Korea
- Geographic restriction (no rights for US/EU/Japan)
Key Highlights
India is the first country in Glenmark’s licensed territories to initiate Phase 3 enrollment following DCGI approval.
The drug (SHR-A1811) has already received Breakthrough Therapy Designation for 9 indications in China, including NSCLC and breast cancer.
Glenmark holds exclusive development and commercialization rights for multiple markets, excluding major regions like the USA, Canada, Europe, and Japan.
The trial is a randomized, multi-centre study evaluating efficacy and safety in patients with HER2-expressing platinum-resistant ovarian cancer.
Glenmark plans to expand enrollment to Australia and South Korea, pending regulatory approvals.
👀 What to Watch
Monitor the timeline for Phase 3 data readouts and subsequent regulatory filings in India and other licensed markets. Success in this trial is a key milestone for Glenmark's transition toward a high-margin, innovative oncology portfolio.
6 US FDA Observations for Glenmark's Goa Facility; No Data Integrity Issues Reported
Glenmark Pharmaceuticals reported that its Goa manufacturing facility underwent a U.S. FDA GMP inspection from June 22 to June 30, 2026. The inspection concluded with the issuance of Form 483 containing six observations. The company stated these are procedural in nature with no repeat observations or data integrity concerns. Management does not anticipate any impact on the supply of commercial products and will respond within the stipulated timeline.
Confidence: HIGH
What changedThe Goa manufacturing facility has moved from a pending inspection status to a post-audit phase with six specific procedural observations to address.
Why it mattersMaintaining U.S. FDA compliance is critical for Glenmark's '3.0 strategy' which targets a revival in the US market. The Goa facility is a key site, and any escalation to a Warning Letter could stall new product approvals.
Number of observations: 6Inspection duration: 9 daysTTM Revenue: Rs 16,983 CrMarket Cap: Rs 61,039 Cr
📅 Short termThe stock may experience minor pressure or neutral sentiment as the market weighs the 'six observations' against the management's assurance of no supply impact.
📈 Long termIf the observations are resolved as 'Voluntary Action Indicated' (VAI), it remains a routine regulatory event. It only becomes structurally significant if the FDA deems the response inadequate.
⚠ Risk flags
- Regulatory escalation risk if FDA is unsatisfied with the response
- Potential delay in new product approvals from the Goa site
Key Highlights
Inspection conducted over a 9-day period from June 22 to June 30, 2026
Form 483 issued with 6 procedural observations
Zero observations related to data integrity were reported by the U.S. FDA
Zero repeat observations were identified during the GMP inspection
Company maintains a TTM revenue base of Rs 16,983 Cr, with US growth being a key strategic pillar
👀 What to Watch
Monitor the U.S. FDA's final classification of the inspection (VAI or OAI) following the company's response. Investors should watch for any subsequent Warning Letters, though the lack of data integrity issues reduces this risk.
Glenmark Launches Methylene Blue Injection in US Targeting $19 Million Market
Glenmark Pharmaceuticals Inc., USA has launched Methylene Blue Injection USP (50 mg/10 mL), a bioequivalent version of the reference drug ProvayBlue®. The launch targets a US market that achieved annual sales of approximately $19.0 million for the 12-month period ending April 2026. This move is intended to strengthen Glenmark's institutional portfolio and provide affordable treatment options in the US. The product will be marketed for specific indications listed in Glenmark's approved label.
Key Highlights
Launch of Methylene Blue Injection USP, 50 mg/10 mL Single-Dose Vial in the USA.
Bioequivalent and therapeutically equivalent to ProvayBlue® Injection by Provepharm SAS.
Addresses a market with annual sales of approximately $19.0 million as per IQVIA April 2026 data.
Strengthens Glenmark's institutional portfolio and focus on the US healthcare market.
👀 What to Watch
This is a positive development for Glenmark's US business, though the market size is relatively small. Investors should track the company's progress in expanding its injectable and institutional product pipeline to drive higher revenue growth.
Glenmark Launches Winlevi® in Europe; Marks First NCE Launch in the Region
Glenmark Pharmaceuticals, through its subsidiary GSSA, has launched Winlevi® (clascoterone 10 mg/g cream) in key European markets including Spain, the Nordics, and Central/Eastern Europe. This represents Glenmark's first-ever launch of a New Chemical Entity (NCE) in Europe, targeting the acne vulgaris market. The product is the first topical acne therapy with a new mechanism of action in over 40 years, acting as a topical androgen-receptor inhibitor. This launch follows a licensing agreement with Cosmo N.V. and strengthens Glenmark's high-margin dermatology portfolio in the region.
Key Highlights
Marks Glenmark’s first-ever launch of a New Chemical Entity (NCE) in the European market.
Winlevi® is the first topical acne therapy with a first-in-class mechanism of action in more than 40 years.
Direct launches initiated in Spain, Nordics, and Central/Eastern Europe, with a strategic partnership in Portugal.
Targets a high-prevalence condition affecting over 95% of males and 85% of females during adolescence.
The product was authorized by the European Commission in October 2025 for adults and adolescents aged 12+.
👀 What to Watch
Investors should view this as a significant step in Glenmark's transition toward innovative and differentiated products. Monitor the revenue contribution from the European dermatology segment in upcoming quarters to gauge the commercial success of this NCE.
Glenmark Targets Global Innovation Leadership with $2Bn Revenue and 60% Branded Portfolio Mix
Glenmark Pharmaceuticals unveiled its 'Investor Day 2026' roadmap, highlighting a consolidated revenue of ~$2 billion and a strategic shift toward a 60% branded portfolio by FY27. The company is focusing on three core therapeutic areas—Respiratory, Dermatology, and Oncology—while leveraging its IGI multispecific antibody platform for long-term value. Key growth drivers include market-beating performance in India with 1.5x IPM growth and a robust US generics pipeline with 2-3 respiratory launches planned for FY27. The company aims to commercialize 1-2 innovative products globally by 2030.
Key Highlights
Consolidated revenue reached ~$2 billion in FY26 with a target of >60% revenue from the branded portfolio by FY27.
India business outpaced the market by 1.5x over the last 3 years, with 11 brands exceeding ₹1,000 million in sales.
Innovation pipeline (IGI) targets one IND filing every year starting FY27, focusing on multispecific antibodies in Oncology.
North America business shows strong diversification with over 86 million prescriptions and a top-3 market share in 74% of commercialized products.
Strategic roadmap aims to commercialize 1-2 innovative products globally by 2030 and achieve therapy dominance in core areas.
👀 What to Watch
Investors should monitor the execution of the innovation pipeline and the ramp-up of the Monroe injectable facility. The shift toward a branded-heavy mix suggests potential margin expansion, making it a strong candidate for long-term portfolios.
Glenmark Launches Lacosamide Injection in US; Targets $15.2 Million Market
Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Injection USP, a generic version of UCB's Vimpat® Injection. The product is approved in 200 mg/20 mL single-dose vials and targets a market valued at approximately $15.2 million as of April 2026. This launch is part of Glenmark's strategy to diversify its US portfolio with more complex injectable products. The company aims to improve patient access to affordable treatments while strengthening its North American business through a differentiated product mix.
Key Highlights
Launched Lacosamide Injection USP (200 mg/20 mL) in the US market.
Product is bioequivalent and therapeutically equivalent to the reference drug Vimpat® Injection.
Targets a market with annual sales of approximately $15.2 million as per IQVIA April 2026 data.
Strengthens Glenmark's injectable product portfolio and commitment to the US generics market.
👀 What to Watch
Investors should view this as a positive step in Glenmark's strategy to build a higher-margin injectable portfolio. While the specific market size for this drug is modest, the consistent launch of bioequivalent products supports long-term revenue growth in the US.
Glenmark Q4 Revenue Up 15.8% to Rs 37,706 Mn; EBITDA Margin Hits 20.2%
Glenmark Pharmaceuticals reported a strong Q4 FY26 with consolidated revenue rising 15.8% YoY to Rs 37,706 million. The North America segment led growth with a 29.4% increase, bolstered by the landmark AbbVie licensing deal which includes a $700 million upfront payment. EBITDA for the quarter stood at Rs 7,626 million with a healthy margin of 20.2%. The company also achieved a significant regulatory milestone with the US FDA EIR for its Monroe facility, clearing the path for future injectable launches.
Key Highlights
Consolidated Q4 revenue reached Rs 37,706 million, a 15.8% YoY growth.
EBITDA margin recorded at 20.2% with PAT at Rs 3,013 million for the quarter.
North America revenue jumped 29.4% YoY to Rs 9,248 million, aided by the AbbVie partnership.
RYALTRIS secondary sales grew over 50% in FY26, now commercialized in 55 markets.
Monroe facility received US FDA EIR with VAI classification, enabling a restart of manufacturing.
👀 What to Watch
The stock remains a strong play on pharmaceutical innovation and global expansion, especially with the AbbVie deal validating its R&D. Investors should monitor the ramp-up of the Monroe facility and the commercial progress of RYALTRIS in the US.
Glenmark Q4 Revenue Up 15.8% to INR 37,706 Mn; FY26 PAT Hits INR 13,620 Mn
Glenmark Pharmaceuticals reported a strong FY26 with consolidated revenue growing 27.5% to INR 169,825 million, significantly aided by a landmark USD 700 million upfront payment from an AbbVie licensing deal for ISB 2001. The company's full-year EBITDA margin stood at a robust 26.9%, while Q4 revenue grew 15.8% YoY to INR 37,706 million. Operational highlights include the US FDA clearance for the Monroe facility and the first generic approval of Flovent HFA in the US market. The India business also outperformed the market, growing at 1.5x the Indian Pharmaceutical Market (IPM) rate.
Key Highlights
FY26 consolidated revenue surged 27.5% YoY to INR 169,825 million, with full-year PAT at INR 13,620 million.
Secured a landmark licensing deal with AbbVie for ISB 2001 with a USD 700 million upfront payment and total potential value of USD 1.925 billion.
India business outperformed the market growth by 1.5x, ranking as the 2nd fastest-growing company among the top 15 in India.
US business strengthened by the first generic approval of Flovent HFA 44 mcg and the restart of the Monroe facility following US FDA EIR.
RYALTRIS secondary sales grew by over 50% globally, with end-to-end commercialization now initiated in the USA.
👀 What to Watch
Investors should look favorably at the significant cash infusion from the AbbVie deal and the resolution of regulatory hurdles at the Monroe facility. The company's ability to outperform the domestic market and launch high-value generics in the US provides a strong foundation for sustained growth.
Glenmark to Transfer Nebulizer Portfolio to Subsidiary GHL for Rs 223 Crore
Glenmark Pharmaceuticals has approved the transfer of its Nebulizer brands and IP portfolio to its wholly-owned subsidiary, Glenmark Healthcare Limited (GHL), for a cash consideration of Rs 223 crore. The business segment contributed Rs 71.6 crore in revenue for the nine months ending December 2025, representing approximately 1.3% of the company's standalone revenue. This internal restructuring is designed to provide sharper strategic focus and operational agility as GHL sets up a dedicated manufacturing facility. The move aims to scale the high-growth respiratory segment, including innovative therapies for Chronic Obstructive Pulmonary Disease (COPD).
Key Highlights
Transfer of Nebulizer brands and IP portfolio to 100% subsidiary GHL for a cash consideration of Rs 223 crore.
The segment recorded Rs 71.6 crore in revenue during 9M FY26, accounting for 1.3% of standalone revenue.
Transaction is based on an independent valuer's report and is expected to be completed by June 30, 2026.
GHL is establishing a new dedicated manufacturing facility to scale the Nebulizer business across India and emerging markets.
The portfolio includes the world’s first nebulized triple therapy for COPD, strengthening Glenmark's respiratory leadership.
👀 What to Watch
Investors should view this as a strategic move to unlock value in a high-growth niche segment by creating a dedicated operational structure. Monitor the ramp-up of the new manufacturing facility and the market adoption of the innovative COPD triple therapy.
Glenmark Recommends ₹2.5 Dividend; FY26 Consolidated Net Profit Rises 30% to ₹13,619 Million
Glenmark Pharmaceuticals has recommended a final dividend of ₹2.5 per share (250%) for the financial year 2025-26. On a consolidated basis, the company reported a robust 27.5% YoY growth in revenue from operations, reaching ₹1,69,825.11 million. Despite significant exceptional items totaling ₹22,660.84 million, consolidated net profit grew by 30% to ₹13,619.52 million. However, the standalone entity reported a net loss of ₹2,007.99 million for the year, largely due to exceptional charges.
Key Highlights
Recommended a final dividend of ₹2.5 per equity share of face value ₹1 (250% payout).
Consolidated revenue from operations grew to ₹1,69,825.11 million in FY26 from ₹1,33,217.40 million in FY25.
Consolidated Net Profit (PAT) increased 30% YoY to ₹13,619.52 million, with Basic EPS rising to ₹48.26.
Standalone performance was dragged into a loss of ₹2,007.99 million due to ₹18,008.58 million in exceptional items.
Consolidated cash and cash equivalents stood at ₹11,747.09 million as of March 31, 2026.
👀 What to Watch
Investors should view the strong consolidated revenue growth and dividend recommendation as positive indicators of business health. However, it is crucial to investigate the nature of the ₹22.66 billion exceptional items to ensure they are non-recurring.
Glenmark FY26 Consolidated Net Profit Rises 30% to ₹13,620 Mn; Declares ₹2.50 Dividend
Glenmark Pharmaceuticals reported a strong 27.5% YoY growth in consolidated revenue for FY26, reaching ₹1,69,825 million. Consolidated net profit for the full year increased by 30% to ₹13,620 million, despite significant exceptional items totaling ₹22,661 million. The fourth quarter showed a massive recovery in consolidated profit to ₹3,013 million compared to a low base of ₹43.8 million in the previous year. The board has recommended a final dividend of ₹2.50 per share for the financial year.
Key Highlights
Consolidated Revenue for FY26 grew 27.5% YoY to ₹1,69,825.11 million
Consolidated Net Profit for FY26 rose to ₹13,619.52 million from ₹10,471.42 million in FY25
Q4 FY26 Consolidated Net Profit surged to ₹3,013.19 million versus ₹43.84 million in Q4 FY25
Recommended a final dividend of 250% amounting to ₹2.50 per equity share
Exceptional items for the year impacted the consolidated bottom line by ₹22,660.84 million
👀 What to Watch
Investors should view the strong consolidated revenue growth and Q4 profit recovery as positive indicators of operational strength. Monitor the nature of the large exceptional charges and the divergence between standalone losses and consolidated gains.
